DRUG-INDUCED LIVER DAMAGE. CLINICAL CASE
Drug-induced liver damage is one of the formidable liver diseases that can appear in the practice of every doctor after the appointment of treatment and lead to a fatal outcome. The described clinical case demonstrates hepatitis that developed against the background of taking basic drugs for the underlying disease. This article describes the course and severity of the disease, the dynamics of the increase in symptoms.
In recent years, the prevalence of drug-induced hepatitis of various etiologies has been growing. The data provided in the article will be useful to therapists, general practitioners, gastroenterologists and rheumatologists.
Шаханова Айжан Тунгышхановна - и.о. доцента кафедры внутренних болезней и ревматологии НАО «Медицинский университет Семей», г. Семей, Республика Казахстан;
Post address: 071400 город Семей улица Абая 103,
E-mail: aizhanshat@mail.ru
Phone: 8 747 685 81 15
1. Chalasani N. et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015. Vol. 148, № 7. P. 1340-52.e7.
2. Björnsson E.S. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. Elsevier Inc., 2013. Vol. 144, № 7. P. 1419–1425, 1425.e1-3; quiz e19-20.
3. Andrade R.J. et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 2019. Vol. 70, № 6. P. 1222–1261.
4. Reuben A. et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010. Vol. 52, № 6. P. 2065–2076.
5. Wei G. et al. Acute liver failure in Sweden: etiology and outcome. J. Intern. Med. 2007. Vol. 262, № 3. P. 393–401.
6. Ohmori S. et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology. 2003. Vol. 50, № 53. P. 1531–1534.
7. Björnsson E. et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. 2005. Vol. 40, № 9. P. 1095–1101.
8. Ostapowicz G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 2002. Vol. 137, № 12. P. 947–954.
9. Wai C.-T. et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007. Vol. 27, № 4. P. 465–474.
10. Brennan P.N. et al. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI). Frontline Gastroenterol. 2022. Vol. 13, № 4. P. 332–336.
11. Andrade R. et al. Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. Gastroenterology. 2005. Vol. 129, № 2. P. 512–521.
12. Chalasani N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008. Vol. 135, № 6. P. 1924–1934, 1934.e1-4.
13. Bessone F. et al. The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. Int. J. Mol. Sci. 2016. Vol. 17, № 3. P. 313.
14. Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 2007. Vol. 167, № 16. P. 1752–1759.
15. Hoofnagle J.H., Navarro V.J. Drug-induced liver injury: Icelandic lessons. Gastroenterology. Elsevier Inc., 2013. Vol. 144, № 7. P. 1335–1336.
16. Amacher D.E. Female gender as a susceptibility factor for drug-induced liver injury. Hum. Exp. Toxicol. 2014. Vol. 33, № 9. P. 928–939.
17. Chalasani N. et al. Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am. J. Gastroenterol. 2017. Vol. 112, № 9. P. 1382–1388.
18. Danan G., Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 1993. Vol. 46, № 11. P. 1323–1330.
19. Zimmerman H.J. Effects of alcohol on other hepatotoxins. Alcohol. Clin. Exp. Res. 1986. Vol. 10, № 1. P. 3–15.
20. Bruno S. et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005. Vol. 330, № 7497. P. 932.
21. Saphner T. et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009. Vol. 115, № 14. P. 3189–3195.
22. Aithal G.P. Dangerous liaisons: drug, host and the environment. J. Hepatol. 2007. Vol. 46, № 6. P. 995–998.
23. Rosenberg P. et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 2007. Vol. 46, № 6. P. 1111–1118.
24. Laharie D. et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J. Hepatol. 2010. Vol. 53, № 6. P. 1035–1040.
25. Dawwas M.F., Aithal G.P. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment. Pharmacol. Ther. 2014. Vol. 40, № 8. P. 938–948.
26. Aithal G.P. Hepatotoxicity related to antirheumatic drugs. Nat. Rev. Rheumatol. 2011. Vol. 7, № 3. P. 139–150.
27. Spyridopoulou K.P. et al. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet. Genomics. 2012. Vol. 22, № 2. P. 117–133.
28. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015. Vol. 63, № 1. P. 237–264.
29. Park S.-H., Choe J.-Y., Kim S.-K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Jt. bone spine. 2010. Vol. 77, № 6. P. 588–592.
Көрген адамдардың саны: 8
Мақалалар санаты:
Клиникалық жағдай
Библиографиялық сілтемелер
Shakhanova A.T., Shakhanov T.E., Kozhakhmetova D.K., Botabaeva A.S., Yurkovskaya O.A., Urazalina N.M., Sabyrbekkyzy N., Shaimardanova K.E., Akhan A.N. Drug-induced liver damage. Clinical case // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (2), pp. 257-263. doi 10.34689/SH.2025.27.2.028Ұқсас жариялымдар:
A CLINICAL CASE OF ECHINOCOCCOSIS OF THE SPINE
DRUG-INDUCED LIVER DAMAGE. CLINICAL CASE
КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ БОЛЕЗНИ БЕХЧЕТА У ЖЕНЩИНЫ 36 ЛЕТ
КЛИНИЧЕСКИЙ СЛУЧАЙ: АНЦА-АССОЦИИРОВАНЫЙ ВАСКУЛИТ (ГРАНУЛЕМАТОЗ ВЕГЕНЕРА) С МУЛЬТИСИСТЕМНЫМ ПОРАЖЕНИЕМ
CLINICAL CASE: POSTSTREPTOCOCCAL ARTHRITIS ASSOCIATED WITH COVID-19